CD8A and neoplasm: This study showed that therapy with BJIKT and pembrolizumab suppressed tumor growth; increased tumor infiltration of CD3, CD4, and CD8; and decreased T cell exhaustion markers, such as LAG-3, TIGIT, and TIM-3, thereby demonstrating the potential to reverse T cell exhaustion in the lung microenvironment.